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Foreword 
On October 16, 1978, Joshua Lederberg was installed as pres­
ident of The Rockefeller University. A Nobel laureate and a 
major contributor to modern genetics, Dr. Lederberg succeeded 
Frederick Seitz, the distinguished physicist who served as pres­
ident for 10 years and under whose leadership The Rockefeller 
University Council was founded. 
As part of the installation activities, the Council sponsored 
a colloquium on the outlook for biomedical research and 
education from the vantage points of the University and its 
two nearest institutional neighbors-Memorial-Sloan Ketter­
ing Cancer Center and Cornell University Medical College. 
The three speakers not only provided unique insights based on 
their individual involvement in the scientific pursuit, but also 
voiced concerns shared by the institutions they represent. Some 
of the major themes emerging from the colloquium were 
explored, eloquently and trenchantly, by Dr. Lederberg in his 
installation address. 
We are indebted to the generosity of The Carl and Lily 
Pforzheimer Foundation that makes it possible to present these 
four statements to the wider audience they deserve. 
JAMES A. LINEN III 
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The Capitalism of Curiosity 
GERALD M. EDELMAN 
Vincent Astor Professor, The Rockefeller University 
Perhaps I should begin by admitting that it is not my habit to attend 
parties of the Jet Set. However, it was once my pleasant fate to attend 
a soiree at which I met Andy Warhol, the artist. He told me, after 
learning that I did scientific research, that he was very interested in 
science. Indeed, he said that he received loads of scientific journals, 
none of which he was able to understand. He found that regrettable 
and then, after some chitchat, he said shyly, "Do you mind if I ask 
you a question?" "Please, go ahead," I replied. He looked up pene­
tratingly and said, "Why does science take so long?" 
I tried to answer this question by drawing analogies to some of his 
paintings of famous movie stars, but didn't get very far. What I tried 
to explain was that a scientist cannot be satisfied only with a beautiful 
image or idea, but must be able to make sure that the idea corresponds 
to some state in the outside world-a rather more difficult enterprise 
than simply imagining beautiful theories. Finally, I tried to discuss 
some of the artistic beginnings of science, because I think that, in their 
initial moments, art and science are very similar. 
I'm afraid I didn't succeed very well in these explanations. I hope 
to do somewhat better today by trying to express some thoughts on 
both the psychology and the economics of basic research, using my 
field-immunology-as an extended metaphor. In particular, I want 
to draw your attention to an idea that lies at the center of immunology, 
both because it has staggering implications in its own right and 
because it offers fertile suggestions for the subject of my talk today. 
My main purpose is to make two general observations. The first is 
that basic research is necessarily an inefficient process. It is not subject 
to ordinary rules of management and stewardship. Instead, it develops 
rich and unpredictable stores of facts and ideas that comprise a kind 
of research capital, which can be spent later for such practical ends as 
the cure of disease. But, like all other capital, most of it can't be spent 
before it is accumulated. Many people think that the line from 
curiosity to application is a straight one; I do not agree. •The fact is 
that research capitalism or the capitalism of curiosity follows a quirky 
and difficult route, in no way subject to the ordinary rules of econom­
ics. 
My second observation is concerned with real capitalism as it bears 
upon the funding of scientific research. There are certain features of 
this funding that no sane capitalist would tolerate in his business. In 
the latter part of this talk, I will explore that assertion, but for now let 
me just state that there is an important link between the capitalism of 
ideas and that of material resources. This link is most indirect, 
however, and to make it effective requires a tolerant and wise view on 
the part of both research administrators and the keepers of the public 
funds. 
Basic research is a reflection of a kind of play. This feature tends to 
be obscured by the technical and planning aspects of research that 
scientists must make one of their major concerns. Nonetheless, I believe 
that the spirit of play underlies most basic research efforts. You can't 
make play efficient without ruining it. If that is true, the imposing 
question becomes: Why pay scientists to play? My reply is that there 
is no other way to assure that proper climate in which fundamental 
discoveries about our world can be made. 
The task of basic research is to discover and describe significant new 
features of the world under the guidance of a surmise, hypothesis, or 
theory. This is frequently misunderstood. Often I've had graduate 
students ask in the middle of an experiment, "Why are we doing this? 
Can't we just go to the library and look it up?" That kind of question 
from students of science might. seem astonishing, but it indicates a 
point of view that is common even in specialized precincts. The answer 
is, one can't look it up-one guesses and one tries. Very often there are 
other misconceptions about the scientific method. Whatever it is, this 
method is not a formula to calculate discoveries. It is something to 
tidy up one's fumbling and guesses 'after one has finally found some 
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apparently coordinated facts or clues. I shall discuss this a bit by using 
immunology as an example, fo order to give you some sense of the 
direction of discovery and research in a basic area with which I am 
familiar. 
Curiously enqugh, backboned animals must do something like this 
guessing and tidying up in order to protect their individual integrity 
by means of immunity-in other words, they must recognize foreign 
molecules by use of their immune systems. Let me indulge in a 
somewhat lengthy digression and consider how this is done. I think 
such a digression may be illuminating, for some of the principles that 
are exemplified by this biological system come close to those that must 
guide basic research itself. 
The problem in immunity is to distinguish self from non-self. To 
put this in a more sophisticated fashion, the immune system must tell 
the difference between the shape of foreign molecules and the shape 
of molecules that belong to a particular individual. The way in which 
the immune system does this is surprising. The system is distributed 
throughout one's body in the bone marrow, in the thymus, which lies 
.just behind the breastbone or sternum, in the spleen, which can be 
found under the left rib cage, and in a variety of small organs called 
lymph nodes, which are distributed all over the body. The immune 
system develops during embryological development and early infancy 
and consists of a rather large number of cells; in a man, perhaps that 
number exceeds 100 billion. These cells, called lymphocytes, circulate 
back and forth in the blood and percolate through a variety of organs 
in the body. They move through various vessels; and finally they 
police the entire body. The only exception is the brain, which is sealed 
off by its surrounding bony structure, and must have other ways of 
handling immune defense. From a narrow point of view, these lym­
phocytes must deal with this problem of defense. But, as I said before, 
from a more basic viewpoint, they make the distinction between self 
and non-self, a fundamental process in more highly developed orga­
nisms. 
The problem, therefore, comes down to one that was first investi­
gated in chemical detail by Karl Landsteiner, who worked in this 
University in its early days as an Institute: How is it possible for an 
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organism to tell the difference in the actual, three-dimensional shape 
of one molecule as distinguished from another? The rough answer is 
by means of a very special molecule called immunoglobulin, or 
antibody. This molecule, which makes the key distinction between self 
and non-self, resides on the surface of the lymphocyte. Ten-thousand 
to a hundred-thousand antibody molecules stick out like little fence­
posts on the lymphocyte surface. Within the lymphocyte is its nucleus, 
containing the DNA with all the genetic instructions; on the periphery 
of the cell is the plasma membrane, which contains the antibodies. It 
is important to point out how small the immunoglobulin is compared 
to the cell-the molecule is so small that it can't even be seen in detail 
by the electron microscope. 
In order to know how this molecule works, we must somehow see its 
structural details. Now, the immunoglobulin molecule has an intrigu­
ing structure with which I have been concerned for about twenty 
years. It is made up of a large number of components, but, as I said 
before, the molecule is still very small compared to the cell itself. A 
few of its structural features are particularly important. First of all, it 
is a T-shaped structure that is symmetrical; the stem of the T sits on 
the cell. At the end of both arms of the T is a cavity known as the 
antigen-combining site; this is the place at which the molecule recog­
nizes a foreign shape. To see what this recognition might be, imagine 
a cookie and a cookie-cutter, if you will, each complementing the 
other; the invading molecule (the cookie)-or the antigen, as it is 
called-enters and is bound closely in each of the two cavities (the 
cookie cutters) of the immunoglobulin molecule. That means that 
these cavities must have a specific shape. In order to recognize different 
foreign molecules, the cavities on antibody molecules affixed on dif­
ferent lymphocytes must have different shapes. Perhaps I should 
change the metaphor-instead of cookies and of cookie cutters, it 
might be better to imagine thes� cavities to be a large number of locks 
into which fit a large variety of unknown keys, which are the foreign 
molecules. 
When the antibody molecules bind foreign molecules, a great 
number of reactions take place: more cells are made, and a variety of 
mechanisms are called into play to destroy or break down the foreign 
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molecules or otherwise entrap_ them. Obviously, this is a major mech­
anism for the body's defense against disease. In bacterial or viral 
invasions, for example, the bacteria or viruses are in some measure 
destroyed or inactivated as a result of this binding process. 
My main concern in trying to do research on immunity has been 
the question: How does this sytem of locks and keys work? This 
question is not easy to answer because of the number of "locks" and 
"keys" one has to deal with. I think you would be startled if I told you 
that, above a certain size, there is hardly any molecule of defined 
shape that the immune system cannot respond to, including molecules 
that have never before existed in the history of the human species or 
any other species. This statement is a close approximation to the truth, 
with some allowance for the special manipulations that have to take 
place within the immune system. 
Now, common sense would tell you that, in order to accomplish 
such a feat, the immune system has to know something about the 
shape of the key before it puts the shape of the lock into place. This 
idea, which is called "instruction" in the field of immunology, has 
turned out to be false and inadequate. During the development of the 
system, no information whatsoever exists on the shape of a future 
invader that is going to be recognized by this system. Astonishingly, 
the system contains all of the necessary potential information before 
it ever "sees" anything out in the world. This is so because it is a 
"selective" system. It does not receive instructions in the way dough 
does when a cookie cutter cuts out a cookie or in the way a master key 
is made by impression from a lock. In fact, the system has so many 
different kinds of locks that virtually any key will fit more or less well 
into one or more than one of them. 
Each of the lymphocytes that I've talked about has its own antibody 
molecules sticking out with their distinctively shaped locks, or cavities, 
waiting for a foreign molecule, the key. When that foreign molecule 
comes along-for example, in the form of a virus of a particular 
shape-it will move along among this collection of cells, and find 
those that bind it more or less well. When the virus does bind, an 
amazing mechanism goes into play that says, "Make more of that kind 
of lock-that is, make more of those kinds of cells and make more of 
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those kinds of antibody molecules with that particular shape of "lock." 
According to the experience the animal has had with a variety of 
foreign molecules, or keys, this command increases the proportion in 
the system of the kinds of locks that happen to fit these keys. This 
principle of selection accounts for responses to transplanted skin, to 
transplanted hearts, to allergies, to typhoid or polio immunizations, 
and so on. The principle is known as clonal selection; clonal, because 
the stimulated cell actually divides to form a clone, or asexual progeny, 
of a single cell. 
This is an astonishing principle. It is obvious that, at a particular 
time, each immune system could not actually have a sufficient number 
of locks to recognize everything in the world. What it does have is a 
very large number of different ways of arranging to build the lock 
portion of different antibody molecules to achieve different shapes. 
The calculated number of potential locks, or antibodies, that can be 
made by such a rearrangement is unbelievably enormous. That process 
is activated very early in each individual's life. When something 
foreign comes along, it encounters many locks as it circulates, and a 
reasonable likelihood exists that it will find one that it fits more or less 
well. 
The surprising feature of this system, which is, in effect, a system of 
discovery, is that it appears to be highly efficient. But fundamentally 
efficiency cannot be the issue, for the system must deal with an unknown
future, one in which the animal cannot tell what foreign material it is 
going to encounter. And the world is very rich in foreign materials! 
Therefore, the immune system is apparently a wasteful system at the 
level of the repertoire of locks that exists in the animal-some will 
never be used at all. But once a lock is encountered, the system is 
extraordinarily effective in amplifying that encounter and developing 
the right kind of antibody .. Perhaps it might be called a learning 
system, in which the body learr�s how to deal with this world full of 
foreign molecules as a result of the very effective way in which the 
selected cells divide and make more kinds of antibodies. The attempt 
to understand this intriguing process has formed the saga of immu­
nology during the last fifteen or twenty years. 
By now we pretty much understand the molecular principles upon 
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which the extraordinary idea of clonal selection stands. Dr. Lederberg 
once published an article on what he called at that time "instruction 
and election" (not instruction and selection), and this article was one 
of the fundamental contributions to the idea that there is a pre­
existing diversity of antibodies. This concept has had deep implications 
for biology. But the story I have told also has a deep implication for 
psychology of research. Because of the unpredictable nature of the 
future and the complex structure of the world, we need in scientific 
ideas and observations the equivalent of a repertoire of different pre­
existing antibodies. Of course, this does not imply that we must not 
plan, use logic, and instruct ourselves as much as possible. But I 
believe that, if you study a scientific problem long enough, you come 
to the conclusion that you will be faced with an irreducible minimum 
of facts and ideas, which, when first conceived, seem to have little 
practical meaning. They seem as gratuitous, if you will, as some of 
these antigen-binding cells with their antibodies. Mind you, the cost 
of having such a system of antibodies is that most of the cells don't do 
anything at all. They simply sit there, live, wait, and die. But this 
"cost" of diversity is the price the organism must pay to get the cells 
that are efficient in their response. The fact that we are all alive in this 
room indicates just how good such a system can be. 
In research, we often don't know the connection between the results 
of our studies and their practical applications. There is one reassuring 
historical point, one made by Lewis Thomas and a variety of other 
knowledgeable and wise people: almost always, apparently inefficient 
basic research pays off handsomely, efficiently, and in unpredictable 
ways. It is obvious that a new vaccine which prevents a major 
incapacitating illness is a vital development in both humane and 
economic terms. What is not obvious are the humane and economic 
benefits of a basic discovery that organizes a field, opens new vistas, or 
makes development of a vaccine possible. What is the dollar-and-cents 
value of the structure of DNA or, for that matter, the founding of 
biochemical genetics, a milestone that Dr. Lederberg helped to mark? 
To take a more personal example, I am always embarrassed when 
reporters ask me to explain the practical benefits of my own work on 
immunoglobulin or antibody structure. That work has cured no 
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disease, but I do think it has helped to reorganize our thinking about 
all diseases related to the immune process and it also allows us to 
envision new diagnostic and therapeutic tools. For example, now that 
we know its structure, the antibody molecule can be cut up in various 
ways and its properties altered in order to treat people more efficiently, 
in ways that the body itself has not yet managed to contrive through­
out evolution. In other words, this kind of knowledge is basic research 
capital, which is ready to be invested in useful and humane projects. 
I must reemphasize that, for the most part, the accumulation of this 
research capital was not in a straight line or for a predicted end result. 
Having digressed so far to make the point that there is a necessary 
inefficiency in accumulating research capital, I now turn to my second 
assertion, which is related to real capitalism and the support of 
research. At the outset, I want to emphasize that I have enormous 
admiration for what has taken place in this country since World War 
II in founding and developing various institutions, such as the National 
Institutes of Health and the National Science Foundation. In partic­
ular, I want to praise the whole system of peer-group review, which 
calls upon scientists to review the merits of other scientists' proposals. 
Nevertheless, it seems to me that there are two areas in which this 
system may be in need of larger insights. These are, first, the failure to 
recognize sufficiently that a fairly large amount of basic research 
capital is necessary before application is possible. In the absence of 
this capital, direct mission-oriented pushes or large task-forces almost 
always fail. Second, to make a more practical point adumbrated in 
my earlier remarks, research support strikes me as a curious form of 
capitalism indeed-one which lacks the usual buffers of space, time, 
or money that a capitalist or a businessman would employ to put his 
funds to the best use. Basic research funds usually are given via grants 
after proposals have been reviewed by scientific peers and agency 
officials, and after the funds ha�e been appropriated by the Congress. 
The funds usually are given according to strict budgets for defined 
periods of time, and this is all well and good. But a close scrutiny of 
the process indicates that if there are any untoward developments in 
a project, or if needs change during the research period, the scientist 
has recourse to only one method-he must reapply over time periods 
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that usually are too long to do him any good or to meet the immediate 
crisis that he faces. And, at the other end, even if an official at the 
NIH, for example, has understood what the problem is, he has a very 
hard time rustling up contingency funds to tide the researcher over. 
The needs for 4ccountability and the political process in some sense 
act in conflict with the needs of the researcher. 
There are related needs, which are particularly striking these days. 
One of them is the increasing cost of setting up young researchers in 
a new research venture-beginning assistant professors, for example. 
Everybody in our kind of enterprise knows that these young brains are 
the ones that we can count on for new developments and new 
imagination. Furthermore, it no longer is possible to have every kind 
of field represented in every good institution. There must be some 
fractionation of fields; this principle has been adopted at The Rocke­
feller University with great success. The question I must ask is, "Given 
all of these needs, would a businessman run his company without 
some form of buffering provided by equity, investment capital, and 
bank loans?" I think it unlikely, and would therefore suggest that 
perhaps the time has come to consider the idea of a research bank, a 
place in which government funds are placed to buffer the various 
situations and contingencies that arise during a research project. Such 
a bank could serve to meet a number of contingencies that confront 
the researcher in the course of his basic research. Let me illustrate this 
a bit by discussing research budgets for a moment. 
A typical budget proposal, taken from my own laboratory, demon­
strates the definite kind of funding system that requires a specific 
budget. The budget must account for the time and effort of the various 
people concerned with a particular project, and include some guesses 
about the kinds of scientific equipment that are necessary. A fairly 
healthy part of the budget is dedicated to research animals and general 
laboratory supplies, as well as to some costs for contracts, publications, 
and shop expenses. But my main point is that this budget, which in 
year one started at $67,000 or so for salaries, grew to $78,000 as a 
result of inflation and other unforeseen contingencies, so that the total 
proportion of the budget dedicated to salaries has become huge. These 
days, the remaining unencumbered funds available to a researcher for 
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a reasonably modest project, such as this one, is a very small percentage 
of the total. Furthermore, a laboratory like mine must make multiple 
requests of this kind to different agencies. If anything happens to 
endanger some of these funds-$11,000 out of a total of $96,000, for 
instance-the project is in jeopardy. The salaries are paid and increase 
with the years, but the project cannot go ahead. Here is a typical 
situation in which a rapid mechanism of buffering of funds insured by 
a loan from a research bank could be of very great use. 
Another area pertinent to this suggestion relates to grant renewal 
and delays in the grant decision-making process. If I have three or 
four grants supported by different agencies with different starting and 
ending periods, a really remarkable juggling act is essential, if a grant 
ends, to keep a constant flow of money coming to the laboratory. It 
requires the cooperation of officials in the various agencies, as well as 
the cooperation of officials in the University. Although a grant is 
awarded in principle, a grant-decision delay means that the money 
simply is not there, and some way of buffering that money must be 
provided. Moreover, as I mentioned earlier, one of the chief challenges 
to a researcher working in this and other universities is to set up 
enterprising and brilliant young people in their new laboratories. 
Unfortunately, because of budget stringencies and delays, this mech­
anism has not been worked out completely within the usual grant 
frameworks. Finally, I think there is some merit in considering the 
establishment of a central clearing house for valuable scientific equip­
ment, which is becoming more and more expensive. A research bank 
might have some function in such a plan. 
Of course, as it stands, this proposal of a research bank is very 
general, and I am aware that there is a conceptual problem: basic 
research provides no direct profit and no obvious tangible product. 
But, as I have tried to show, science has an invisible product with 
enormous implications for our_ economy. Indeed, some economists
have estimated that over 30 percent of the economic development in 
this country since World War II can be related in a more or less direct 
way to the basic research accomplished in that period. Moreover, I 
am told by people such as Gus Kinzel, former director of research for 
Union Carbide, that basic research is much less costly than applied or 
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developmental research. For e�ery dollar dedicated to basic research, 
he tells me, about $10 must be spent on applied research, about $ 100 
on development, and $1,000 on plant. Basic research, essential basic 
research, is cheap, given the return. 
I know how much work would have to go into thinking through the 
practical details of a research bank. This is not the place for these 
matters, and the idea may not be practical in the end because of the 
political difficulties. All the more reason for institutions like The 
Rockefeller University, the President's Office of which already serves 
many of the functions of a research bank, as I suspect Dr. Lederberg 
has already found out. Indeed, it has always been a local tradition 
here to provide some of the buffers that I have been talking about, but 
it is a hard tradition to maintain in the face of mounting costs. Clearly, 
we must continue to receive support from enlightened private sources, 
for that support has been one of the key reasons this place has 
remained excellent. I join with the others here in the justifiably 
optimistic hope that Dr. Lederberg will deepen and adorn the great 
tradition of the capitalism of curiosity at The Rockefeller University, 
a tradition composed of both private and public support, of indepen­
dent laboratories, of magnificent ancillary services, and of a fervent 
belief in the intellectual excellence of the workers, tempered by an 
understanding of how that excellence is achieved. That understanding 
stands upon the principle that basic research does not run in a direct 
line from curiosity to achievement and use. 
So, as I said to Mr. Warhol, perhaps too lugubriously and with a 
personal poignancy I needn't discuss, "Science does take a long time 
to do well." Given that, researchers must have the freedom and the 
time to pursue their ideas. In an atmosphere of mounting frenzy and 
push programs, which-at least in the public sector-seem to be more 
and more prevalent, perhaps it would be well to remember that ideas 
do not come every day. Certainly good ideas don't come every day. I 
cannot help paraphrasing in a somewhat inexact but essentially correct 
way the story about Paul Valery, the French poet, who went to visit 
Einstein because he was interested in poetic creativity and scientific 
creativity. He asked, "What do you do every day?" Einstein said, 
"Well, I get up and shave and I take a walk and I think, and by that 
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time it's lunch and then I'm a little tired, and I think a little more in 
the afternoon, but by that time I'm really tired, and I have supper 
and I go to bed. Perhaps I have a sail or another walk, but that's 
about it." Valery said, "Do you keep a notebook?" Einstein looked at 
him, startled. "What on earth for?" he said. "You know, to write down 
your good ideas." Einstein said (and I believe this is a true story), 
"Look, I don't get many. And don't worry, when I get one, I don't 
forget it." 
Once having assured the quality of a research climate, I believe that 
the best policy is to leave the researchers alone to their play. That is, 
do not get in their way, for an excess of zeal leads only to logic rather 
than to imagination. I would like to end with one comment and one 
further anecdote. The comment is by William Butler Yeats, who was 
a great poet but, unfortunately, a great enemy of science. Nonetheless, 
he obviously understood imagination and creativity. He said that bad 
art is will substituting for the imagination. This is also true of science. 
Bad science, fundamentally, is will substituting for the imagination. 
The anecdote is told by Freud. During the Napoleonic Wars, an 
emergency was anticipated and Napoleon called his councils of war 
and consulted his generals about what should be done. An old general 
said, "The most urgent thing to do is wait." To my mind, this a good 
description of the psychological tone of doing basic research. It is 
dominated by the urgency of waiting. No highly structured or pro­
grammatic approach will succeed as well as that form of urgency. In 
places like The Rockefeller University, with the love that its scientists 
haye for their discipline and their art and their science, we have 
nothing to fear about the absence of urgency. 
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Medical Education and Biomedical Research 
THEODORE COOPER 
Dean, Cornell University Medical College 
This is a happy occasion for all of us-for different reasons. We at 
Cornell are excited and expectant. We congratulate The Rockefeller 
University; we congratulate President Lederberg; and we even con­
gratulate ourselves. Indeed, we are fortunate to be your close neigh­
bors, your colleagues, and, we hope, your partners in many future 
scientific and educational endeavors. 
Among the many challenges and opportunities that you will con­
sider, some are specific to the York Avenue institutions. Among the 
greatest of these is the achievement of the promise raised by the 
proximity of three great institutions with some common heritage, some 
common purpose, some common programs, some common problems, 
some common needs, and many uncommon people and ideas. This 
commonality-an old dream that I have heard ascribed to many of 
you here today-should take real form now, because in our own ways 
we all need it; New York needs it; the American systems of biomedical 
research and education need it, not for survival, but to be able to 
prepare for the future. 
It is not difficult to convert happy occasions such as this into gloomy 
ones simply by reporting most of the discussions being held by national 
leaders in medical education and research. The commentary can only 
be characterized as ambivalent, guilt-ridden pessimism. We are being 
convinced that we are guilty of fraud, financial irresponsibility, and 
failure. Indeed, for a system that has done so much good, it is 
remarkable how it can be perceived as so bad. The explanation of this 
perplexing and frustrating situation lies in the changing criteria of 
social justification and evaluation. 
We in this country have accepted as appropriate and right that the 
government should support medical research and medical education. 
We have· gone further. We have said that, in the public interest, the 
government should support a very large portion of the costs of medical 
research and education, and we have attempted to develop a system 
of public and private institutions that could react to these assumptions 
as if the institutions-public and private-operate the same way. 
The character of medical education has been greatly influenced by 
research activities in our institutions, even to the extent that faculties 
have been refashioned and facilities redesigned. The remarkable im­
pact of research can be seen on medical practice. And as medical 
practice changes, so does the educational process. Thus, research has 
had both direct and indirect influence on medical education. Financ­
ing has been a factor; the character of the faculty has been a factor. 
No longer is the philosophy dominated by "the practitioner." The 
students are selected by people with different viewpoints. The empha­
sis, the orientation, has changed. Medical education presents other 
unique reflections of the realities of financing. Large and growing 
amounts of money from practice are underwriting faculty salaries. As 
federal research funding is increasingly unable to meet the cost 
patterns that were set ten years ago, practice plans are being looked 
into in order to bridge the gap between commitments and institutional 
resources. Faculties are rationalizing these changes by agreeing that 
perhaps such plans could come close to income parity with the private 
practitioner. 
At the moment, no greater force challenges our philosophies of 
operation than cost escalation in medical care. So pervasive is this 
concern that no sector-education and research included-is free from 
suspicion of "fat," excesses, waste, greed, and irresponsibility. So loudly 
and often have the charges been made that the allegation is now the 
conclusion. As a consequence, we are accepting refinancing without 
changing aspiration or expectat�on. We are not even willing to suggest 
that perhaps it is not possible to do all things with less money. We are 
reluctant to challenge government-mouthed righteousness, because we 
do not wish to offend those who administer our monies. This is a well­
recognized consequence of dependence-the loss of flexibility that 
accompanies the "emperor's new clothes" syndrome. 
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Social justification is being interdigitated with scientific evaluation 
in an interesting but dangerous way. It is one thing for society to 
decide "it isn't worth it," but quite another to conclude that not being 
worth it means that it has no intrinsic merit or, worse, that it was 
undertaken with malicious deceit in mind. In order to attempt to meet 
every possible objection, every human failing, the government is 
attempting to direct the system, to achieve social objectives, and to 
guard against abuses by creating more and more specific restrictive 
legislation and regulations. In a very real way, the proliferation of 
rules and reporting systems is a greater problem than are the deficits 
of funding for our institutions. 
As one reviews the forthcoming legislative calendar, no matter what 
item is encountered, one is faced with recidivism in various ways: 
1) The Health Professions Education Bill will lead to requests for
more federal direction of who can go to medical school and what 
should be taught. At the same time, there will be withdrawal of 
funding and increase in control. The student loan provisions and 
regulations are already incredible. For a loan of $30 + thousand, the 
student is expected to pay $140 + thousand. 
2) The Research Authorization Bills will attempt to change empha­
sis, will increase reporting, and will decrease promises of future sup­
port. The administration's new "plan" will not have significant impact 
for the next two years and, if it did, it would be to "cap" the system 
in the name of stability. 
3) The Health Planning Legislation will intensify the regulatory
activities of local bodies. Medical colleges will be increasingly involved 
and ensnarled. As dependence on clinical-practice income increases, 
our vulnerability to political manipulation increases. 
4) Measures to change practice through financing will receive the
greatest attention. Reimbursement for teaching hospitals will be 
changed in efforts to reduce costs. Limits on incomes will be proposed. 
Limits on services also will be proposed, while at the same time more 
and better care for everyone through National Health Insurance will 
be promised. 
5) The Drug Reform Act and some recent regulations relating to
clinical investigation in academic centers, proposed by the Food and 
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Drug Administration, will magnify reporting, recording, and review­
ing, way out of proportion to any benefit they could possibly obtain. 
6) The Federal Trade Commission will pursue the health professions
with the doctrine of salvation through competition. 
The list is long and, if looked at in isolation, presents a• depressing 
picture. But federal brushes should not be painting the whole canvas. 
There are several encouraging signs. The most important of these is 
the revival of intellectual independence in our private institutions. 
The evidence is substantial: the refusal of capitation funds by several 
institutions rather than acceptance of federally dictated admission 
policy; the successful campaign against restrictive DNA legislation; 
the successful campaign against implementation of Sec. 227 of the 
Medicare Law; and a meaningful modification of the Office of Man­
agement and Budget circular A-21 on overhead determination. 
The biomedical researchers, the medical colleges, and the health­
science centers are less reluctant to work openly with business, partic­
ularly with the industrial world. Part of the reason behind this 
conversion is financial self-interest. Yet it is a very important evolution. 
The admirers of the American system of enterprise can come out of 
the closet. The association with government is no longer free of 
implications of control and direction. And, in fact, there is growing 
concern that the directions a required and the controls imposed by 
government are less and less justified on appropriate social grounds, 
not to mention scientific and academic critera. We would be well 
advised to restore independence through balanced pluralistic interac­
tion. We should be making scientists, physicians, and other health 
professionals aware of the career potential in nonacademic and non­
governmental settings. 
One can even make the remarkable observation that the academic 
and practicing wings of the medical profession have come closer 
together. "Organized medicine" �as helped the academic brotherhood 
in meaningful ways in Washington by lobbying for legislation that is 
helpful to medical schools and the scientific community, including 
appropriations for the National Institutes of Health and sound posi­
tions for education legislation in the health professions. These have 
put a different perspective on the "town-gown" situation as we move 
16 Theodore Cooper 
into the need for rapid integration of_ new knowledge into clinical 
practice through education. The busy practitioner knows he has a 
reliable friend and critic in the academic scientist-physician who can 
help sort out the meaning and quality of newly proposed methods of 
diagnosis and treatment.· 
Yes, not all the signs are negative. The list of positive trends, like 
the apparent success of the voluntary cost-containing efforts, is grow­
ing. But the most important reason for optimism lies in realizing how 
much we are going to be able to do for people in the future. Social 
and scientific forces will insure high interest, growing expectation, and 
need for innovation, experimentation, and education. Too many 
people have viewed modern medical technology as approaching the 
ceiling of possible intervention on disease treatment and prevention. 
Dr. Lewis Thomas has repeatedly warned of this short-sightedness. If 
one looks ten years down the road, the possibilities are staggering. 
From immunology, genetics, neurosciences, behavioral science; from 
pharmacology; from bioengineering will come great insights and tools 
for the practice of general medicine, not superspecialty medicine. 
The "new-old" panacea for our social-medical ills, i.e., preventive 
medicine, will take on new meaning because we shall have real tools 
to find the susceptible, to make predictions far beyond statistical 
correlations alone. We shall be able to interpret biological response to 
social ills with confidence. 
At our medical college, we have begun the process of preparation 
for tomorrow. We have recognized that we can no longer do business 
in the same old, comfortable way. We accept that there are limitations 
to our resources, but not to our vision. To avoid becoming a part of a 
seedy, aristocratic home of solid mediocrity, we shall seek to improve 
our productivity. We shall regain independence of action through 
reduced dependence on government. Cornell Medical College spends 
about one-third of its resources on research, one-third on education, 
and one-third on services. We shall repartition our "hard monies" in 
favor of the support of education and science. We shall redesign our 
clinical programs with The New York Hospital and our other affiliates 
to provide more service to the community at less cost per citizen. The 
future of clinical teaching will demand diversjfication, a broader 
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variety of clinical experience. The aggregate expenditures for clinical 
service and education will increase, but will derive from various 
sources. The national refinancing of health services implied in what is 
called National Health Insurance will offer both opportunities and 
problems. The problems are conceptually manageable, at1d we need 
to get on with preparing how to accommodate them. 
Our independence-our productivity and our ability to dream­
will come through.strong associations with The Rockefeller University 
and Memorial Sloan-Kettering Cancer Center. Therefore, we wish 
you success, for we cannot help but grow with you. 
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The Competing Roles of Basic and 
A pp lied Research on Cancer 
LEWIS THOMAS 
President, Memorial Sloan-Kettering Cancer Center 
It is a privilege to be here today, on this great occasion in the life of 
The Rockefeller University, and a quite special and personal pleasure 
for me as an alumnus of the venerable Rockefeller Institute, as a 
trustee, and as a representative of Memorial Sloan-Kettering. My 
remarks this morning are made in this latter capacity. I want to 
explain some things about what my institution is up to, just across the 
street. It is not widely known that Memorial Hospital was placed 
where it now stands, 40-some years ago, because John D. Rockefeller, 
Jr. was convinced that cancer research and patient care were going to 
need this proximity to both The Rockefeller University and Cornell. 
First off, I'd like to say something candid, ambitious, and self­
interested about the future of Memorial Sloan-Kettering. Obviously, 
we have a single, very long-range mission as our assignment from 
society: to do whatever becomes possible to do in order to reduce the 
threat of cancer, and, in the best of worlds, to get rid of it. This mission 
is self-evident from our title and charter, and the ambition to get this 
accomplished is what drives the place along. However, there is another 
mission and ambition in the back of the minds of many of us. It is to 
form intellectual linkages as close as possible with both our distin­
guished neighbors, the Rockefeller and Cornell, so that all of us can 
capitalize on the lucky creation, here on York Avenue, of as concen­
trated an aggregation of scientific firepower as exists on a single city 
corner anywhere in the country. 
I am convinced that there are new symbiotic arrangements that can 
be worked out among these three institutions that could have the 
effect of greatly enhancing the kind of science done here, particularly 
in such times of inadequate funding for biomedical science as surely 
lie ahead for all of us in the next decade or more. Moreover, I am 
convinced that closer ties among us, if worked out carefully and with 
taste-which means, in my view, with a good deal of informality and 
looseness, and worked out by the faculties concerned-would have the 
net effect of making it enormous fun to work here, especially for those 
generations of the brightest young people, in training for careers in 
science, whom we all hope to see agitating back and forth across 68th 
Street and across York Avenue. It goes without saying that the quality, 
braininess, and enthusiasm of the very youngest people, those just 
beginning their scientific careers, provide the most certain and exact­
ing test of success for institutions like these three, whatever the 
differences in our structure and mission. 
And, of course, there are great differences, needing understanding 
and frequently needing explanation. Across the street, Memorial 
Sloan-Kettering is a single-mission institution, dedicated to the con­
quest of a single disease. This suggests to some observers, at a distance, 
that our science must be highly targeted, programmed in every detail, 
and squarely in the area of what is called applied science. It is 
abundantly not so. On the contrary, virtually all of the research in the 
Sloan-Kettering Institute, amounting to about $30 million per year, 
would have to be classed as basic research, if this term is taken to 
mean, as I mean it, the exploration of tentative hypotheses in an 
atmosphere of high uncertainty. It is this matter of uncertainty that 
defines basic research, in my opinion, and differentiates it from applied 
science. All of us can make guesses about the underlying mechanisms 
which are responsible for switching a normal cell into the mode of a 
neoplastic cell, but none of these guesses can be regarded as anything 
like a sure thing. The research has to be based squarely on making 
guesses, and for a biological problem as broad and profound as cancer 
it is necessary to cast a very wide net, and to make up stories, 
hypotheses for testing, in many different fields of biology. The labo­
ratories of Sloan-Kettering are engaged in this kind of enterprise, 
covering as v.ride a cut as is logistically feasible of the fields that seem, 
at a guess, to be somehow or other relevant to the underlying process 
of neoplasia. 
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Research of this kind cannot really be targeted, nor can it even be 
centrally controlled or run by committees within an institution; it 
requires the imagination and mind-changing of individual investiga­
tors. For instance, there are some pretty good reasons for supposing 
that immunologic mechanisms may be involved in natural defense 
against cancer, and it can be imagined that most of us do not develop 
cancer because of the proper functioning of such mechanisms, but in 
order to study this matter it is necessary to learn a great many things 
about immunology itself, in general; the time has not yet arrived for 
the launching of any kind of applied targeted research program for 
immunology in cancer; there is nothing resembling certainty here; it 
is plainly a matter needing basic science of the most uncommitted, 
undifferentiated kind. The same thing must be said for our programs 
in virology, in molecular genetics, in cell differentiation, in aging, and 
all the rest. None of us can predict, with any sort of assurance, whether 
or when any one of the lines of research will turn out to be actually 
connected with the cancer problem, in the sense of being useful or 
usable. It is something like gambling, but there is, in real life, no other 
way to go about it. 
Meanwhile, there is a certain amount of applied research that can 
be done, and must be done. Despite the plain fact that we are nowhere 
near to the center of things in the problem of cancer, there are some 
extremely useful measures that can be taken to treat the disease, and 
these must be tested, tried out, and improved upon if possible. This 
kind of research consumes the energies and time of a large group of 
clinical investigators in Memorial Hospital; most of these people hold 
simultaneous appointments in the Sloan-Kettering Institute and work 
side by side with their colleagues in the basic research laboratories. 
Therapeutic research is the hardest and most demanding of scientific 
endeavors. It has to be done in a totally different mode from basic 
research. In the first place, it can only be done well when highly 
centralized, carefully programmed protocols are laid out in their most 
intricate details, way in advance; committees are essential for both the 
planning and the operation. You cannot go around changing your 
mind whenever your mind feels like changing, which is the greatest 
difference from what goes on in basic research (which, as I've said, 
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works by mind-changing). Once a protocol is laid out and agreed upon, 
everyone involved is expected to follow that protocol with precision 
until the results come in. Biostatisticians stand as indispensable arbi­
ters, before, during, and after the work. 
We do not have a long history of first-rate applied science in 
medicine, primarily because it is only quite recently that we've had 
much in the way of genuinely basic information to apply. The best of 
our achievements thus far have been in the field of infection, and there 
may be a useful analogy here for the understanding of where we are 
heading in cancer research. 
I was a medical student in the mid-1930s, when tuberculosis was 
the disease of most concern. Anyone, from infants to the aged, was at 
risk. If you were lucky, you survived. If the diagnosis was made early 
enough, and you were admitted to one of the many ·state hospitals or 
private sanitaria devoted exclusively to TB patients, your chances of 
survival increased. Rest was the only treatment-both for the body 
and for the lung itself-by inducing its temporary or complete collapse. 
No drugs helped. 
It was also 1 ucky if the disease did not spread. If the bacilli reached 
the central nervous system, that was the end. The doctor's main 
function in tuberculosis meningitis was to make the end peaceful for 
the patient and to comfort the survivors. 
From the 1890s, when Koch discovered the tuberculosis bacillus, 
basic research on the disease expanded worldwide well into the 1930s. 
Gradually, investigators began to understand how tuberculosis spread 
through communities, and early detection and isolation methods were 
developed. The still-mysterious mechanisms that enable the tubercle 
bacillus to destroy living tissue were explored, and environmental 
factors were identified: crowding, malnutrition, genetic predisposition, 
immune responsiveness, perhaps even the stress of living. 
But throughout forty years, the single, crucial discovery was that 
the tubercle bacillus was the sole cause of the disease. Other factors, 
environmental or genetic, might contribute, but at the center, indis­
putably, lay the bacillus. If it could be killed and the patient live, 
tuberculosis could be cured. This achievement led ultimately to the 
work of Selman Waksman, who, like Rene Dubos, explored the hunch 
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that certain soil microorganisms might produce chemicals that could 
curb the growth of competing bacteria. 
But streptomycin was not good enough; it cured only those patients 
in beginning stages of the disease. It could not reverse consistently the 
devastations of miliary TB or TB meningitis. Also, it produced disor­
ders in hearing and sense of balance if used over long periods or in 
large doses. Nevertheless, streptomycin proved that the tubercle bacil­
lus was vulnerable in living tissues and, subsequently, research led to 
para-aminosalicylic acid and then to isoniazid. Tuberculosis became, 
at last, a curable disease. 
We do not yet possess information about cancer with anything like 
the central significance of the tubercle bacillus in tuberculosis. Of 
course, today we have clues that were unknown twenty-five years ago. 
We know for sure that cigarettes are the main cause of lung cancer. 
We are certain that other environmental pollutants, notably asbestos, 
are implicated in various forms of the disease, and new agents, from 
hair dyes to food additives, come under suspicion with remarkable 
frequency. 
But the identification of environmental carcinogens will not by itself 
solve the problem, when they are as ubiquitous in nature as now 
appears to be the case. We need to know the nature of the mechanism 
in the cell which triggers its transformation from normal to neoplastic 
activity. It has been suggested that a virus or some other infectious 
agent is involved, although the idea seems less plausible now than it 
did a few years ago. The switching mechanism remains a mystery, 
and it is this problem that constitutes the major preoccupation of basic 
science in cancer research today. 
However, there is progress in cancer therapy despite the lack of 
fundamental information about the process. Twenty-five years ago, 
very little could be done in the way of specific or selective therapy, 
and nothing could be done to prevent or restrain the metastatic spread 
of cancer to other parts of the body. 
Then treatment with chemicals became part of the arsenal. The 
earliest chemotherapy was the use of nitrogen mustard, which is 
related to the mustard gas of World War I. Some cases of leukemia 
responded remarkably well, but the side-effects of the treatment were 
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alarming and sometimes lethal. Modifications of the drug were intro­
duced, then totally novel compounds, all with the capability of 
interfering with the functions of rapidly dividing cells, and it became 
clear that certain varieties of cancer were highly vulnerable to these 
chemicals. 
Even ten years ago, leukemia could be arrested in 50 percent of the 
children affected, and other forms of cancer regressed as a result of 
chemotherapy, even if only for short periods. The past five years have 
produced more dramatic results. Hodgkin's disease is now curable 
when treated in its earliest stage. Combinations of less toxic drugs, or 
drugs plus radiation therapy, have given reason for hope-as in bone 
sarcomas of children-that we can talk tentatively of cures. The 
treatment of testicular cancer by use of platinum salts has recently 
been spectacularly successful. 
Obviously, not all forms of cancer respond equally well. We have 
not found the right drugs; we have not found the right combination 
of treatments. Most importantly, that triggering mechanism still eludes 
us. But discoveries are coming faster and faster. 
How did we get to this point? Do the improvements in our tech­
nology for treating cancer thus far represent a feat of appled science, 
or were they based upon basic science? It was, and is, a mixture of 
both kinds of enterprises. At the outset, it was entirely empirical, and 
for some years after nitrogen mustard, most of the effort consisted of 
screening great numbers of compounds for anticancer activity, more 
or less blindly. In recent years, however, it has become a considerably 
more sophisticated undertaking, with molecular design now made 
possible by today's more basic understanding of the kinetics of cell 
division; it is now feasible to synthesize new drugs that are aimed at 
interrupting one stage or another in the cell cycle, and both the 
potency and the reduction of toxicity are problems that are open to 
research by groups of chemists and basic pharmacologists such as those 
now working in the Sloan-Kettering Institute, together with the 
clinical scientists in Memorial Hospital. 
The limitation of this line of research is well recognized by everyone 
concerned. It is not really a specific anticancer therapy at all, any 
more than radiation, even the extremely precise and effective forms of 
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radiotherapy now used for H?dgkin's disease, is specific anticancer 
therapy. The technology is aimed at rapidly dividing cells, and we 
will be held at this level until we have learned more about the special 
attributes and points of vulnerability of cancer cells themselves. It is 
the best we can do at the present time, and it is certainly not the final 
answer. But it does work, nonetheless, in some patients with some 
forms of cancer, and it is still open to further improvement by research. 
This kind of research can only be done by close collaboration between 
basic and applied scientists, and it cannot be done at all without the 
resources of clinical institutions like Memorial Hospital. 
One very bright piece of news has come from all the work in 
chemotherapy to date, and is often overlooked by the public, by critics 
of the National Cancer Program, and especially by those critics who 
believe (as I do not) that cancer can be reduced to a minor health 
problem by changing the environment to prevent it; you could, I 
agree, accomplish a great deal by eliminating cigarettes, and the 
identification and elimination of industrial carcinogens is clearly a 
worthwhile activity to which all of us ought to be committed. But it 
is highly unlikely, I think, that we will ever find them all and, even if 
we could, it is still more unlikely that we can change the way our lives 
are lived drastically enough to get rid of them all. We simply do not 
know enough yet to talk about preventing most forms of cancer, even 
though this is the most laudable of objectives for applied science in 
the long-term future. And even when we do know all there is to know 
about the environmental causes, we are still going to have to face 
cancer as a formidable health problem, and we are going to have to 
treat it. 
The bright piece of news is that cancer is, really, slowly, gradually, 
becoming a treatable disease. I do not say this out of any institutional 
self-satisfaction, nor with anything but discontent with today's forms 
of treatment; they are not good enough, they do not cure enough 
patients, and they are not directed at any central, causative mechanism 
of the disease. Nevertheless, from time to time, much more often today 
than just five years ago, they do work, spectacularly well, and this 
means.something quite tremendous, to me, anyway. Even twenty-five 
years ago, I would have said that such a thing would be forever 
Basic and Applied Cancer Research 25 
impossible. I believed that cancer was simply a fact of life, a part of 
the human condition, like mortality, a sort of tax on living in com­
plexity. But today, to observe the rapid vanishing of huge growths in 
the lung almost overnight, the shrinking almost to nothing of great 
masses of malignant cells in the brain, is an absolutely extraordinary 
thing to see, despite the knowledge that some of the cells are still alive 
in there and will grow back again, sooner or later. We need a new 
technology, perhaps an array of new technologies, to assure the 
elimination of those last, still invulnerable, cells, but I have no doubt 
at all that this can be done. It will not happen easily or quickly, and 
we have a vast amount of basic science still ahead to do. Then there 
will have to be other vast efforts in applied science, but I see no reason 
at all to be skeptical on this issue. Cancer is no longer the blank 
mystery it seemed, not very long ago. It has become an approachable, 
ultimately solvable biological problem. 
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INTRODUCTION OF PRESIDENT LEDERBERG 
PATRICK E. HAGGERTY 
Chairman of the Board of Trustees, The Rockefeller University 
In three-quarters of a century, The Rockefeller University has had but 
four leaders-Simon Flexner, Herbert Gasser, Detlev Bronk, and Fred 
Seitz-and it has been fortunate in all of them. 
Once again, in Joshua Lederberg, the University is fortunate to 
have found a leader for the future who is qualified to match the 
expectations created by this institution's experience with those who 
have preceded him. 
A scientist with a deep concern for improving public understanding 
of science and its role in society, he comes to us from Stanford 
University's School of Medicine, where he was chairman of the 
Department of Medical Genetics and Joseph D. Grant Professor of 
Genetics. A man of far-ranging interests, he has been active on a 
variety of advisory committees and boards dealing with an equal 
breadth of problems, including those of mental health and retardation 
and environmental health. Winner of a Nobel Prize in 1958 at the age 
of 33, Dr. Lederberg is an exceptionally gifted scientist of international 
stature, one of that band of pioneers who has laid the foundations of 
modern genetics, a field that is furnishing new techniques and valuable 




President, The Rockefeller University 
First of all, my welcome to you to this exhilarating occasion, and my 
particular thanks to those of you who have come a long way from all 
parts of the world. I am also especially pleased to see those of you who 
have traversed 68th Street or York Avenue in the mood of fellowship 
and cooperation that should increasingly bind our respective institu­
tions. 
Why would so many people go to such trouble for an event of this 
kind? Anyone who has ever had to arrange for more than a dozen 
people will respect the fuss and labor that it must entail. From my 
own perspective, a ceremonial like this mainly gives pause to a new 
incumbent, and to a venerable institution, for a process of self-exam­
ination from which both may profit. 
I am reminded of James B. Conant's admonition describing the 
beginning of his long service as president of Harvard University, after 
having returned there from a distinguished career as a laboratory 
organic chemist. How grateful he was, he wrote in his autobiography, 
that he was inadvertently thwarted in his plan to publish his initial 
thoughts on entering: " ... that would have hung around my neck 
during the next 20 years like the albatross of the ancient mariner." 
But I am going to disregard his implicit advice, as indeed I have 
tried hard to exhibit other disqualifications for an administrative role, 
by trying to continue to behave as a laboratory scientist. In the latter 
role, it is important to bring speculative ideas to the surface, where 
others, as well as myself, can have a better opportunity to criticize, 
sometimes even to discard, them. Furthermore, the scientist should be 
quite fearless about appearing to be naive, ignorant, or even foolish­
too often if you think you know the answer, you don't understand the 
problem! My remarks are, then, in no respect settled truths, but reflect 
initial quandaries and dilemmas in my trying to understand the larger 
aspects of new responsibilities. 
The fact is that none of our institutions can evade the most critical 
examination, in the present climate of skepticism and inquiry about 
our entire social fabric. If we do not examine and sometimes reform 
ourselves, others will do so with even less information and insight. This 
is then an apt moment to ask, as we should be prepared to ask at any 
moment, "Just what would be lost if we disappeared from the face of 
the earth?" 
Perhaps there is even some special advantage in an incumbent's 
tackling these issues before he is indeed encumbered by his day-to-day 
obligations, and before he is embraced by the traditions and setting of 
an institution so manifestly captivating as to prejudice that essential 
self-examination. In fact, before proceeding more broadly, there are 
two local elements of our setting worthy of comment. 
First, this is the season of the equinox, with its unpredictable 
alternations of climate and mood. In the ancient traditions of my co­
religionists, the community built the harvest tabernacle as a symbol of 
the indispensibility and frailty of our human constructions, of reliance 
on a benign Providence for the recurrence of the nourishing rains, and 
as a shelter against the torrential winds. In pursuing our academic 
plans, we must still rely both on optimistic faith in ourselves and on 
the support of a larger community. 
In the crass terms of modern industrial society, a one-percent 
fluctuation in the rate of inflation is the margin between fiscal stability 
and disciplined growth on the one hand, and an inexorable slide into 
insolvency on the other. We may congratulate ourselves in being far 
closer to equilibrium today than are most other private academic 
institutions. The most onerous and demoralizing adjustments-the 
painful task of my predecessor Dr. Fred Seitz-are already behind us. 
With hard work and just moc.lerate good luck, we have a planning 
framework for vigorous survival. But it would take an egregious hubris 
to ignore the possibility of still other unforeseeable storms; and we 
must remind ourselves unremittingly how vulnerable we are to the 
smallest fluctuation in public understanding of the integrity and 
necessity of our mission. The task we face is both a material one of 
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matching our plans and operations to a realistic model of the resources 
available, and the spiritual one of sustaining our own confidence in 
the importance of our work, and of communicating and shaping it to 
the best interests of the human purposes we ultimately serve. 
Another element in the setting for my remarks is the 75th Anniver­
sary celebration of The Rockefeller University, held just two years 
ago. Much of what I would want to say myself was already captured 
by the statements of others at that time. Those accounts of the 
transition from The Rockefeller Institute of Medical Research to The 
Rockefeller University depict what attracted me to this place: not to 
invoke radical changes, but to conserve the most vital traditions of 
biomedical research to be found anywhere today. 
It has become almost tedious to use this indicator, but of course we 
do take some pride that still another of our research alumni, Dr. 
Daniel Nathans, was honored with the Nobel Prize, announced just 
last week. Dr. Nathans graduated from his clinical residency into 
laboratory research here under the tutelage of Professor Fritz Lipmann 
from 1959 to 1962, and I am sure that we all join in collegial 
congratulations to him. We cannot be doing everything wrong with a 
consistent record of recognition represented by the placement of 
Rockefeller University graduates in leadership roles in medical re­
search and education throughout the country. 
The fundamental agenda of The Rockefeller University is indeed 
basic biomedical research of substantial breadth in the tradition of 
the Institute. The biomedical laboratory is the central focus of medical 
research today: but it must have a still broader perspective-that of 
the biochemical laboratory. We are fortunate in a faculty of world­
recognized excellence in the behavioral sciences, as well as in experi­
mental biology and pathology. And we can be informed by the still 
different insights of physics and mathematics. 
Now, scientific research is one of the most enthralling games that 
can occupy the human mind, and those of us who can dedicate our 
lifework to it are privileged indeed. But the private excitement of the 
chase for new discovery should not obscure the enormous public stakes 
of the enterprise-stakes that are trivialized by the attribution of mere 
curiosity or by the better-selling Frankenstein images of the pop media. 
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What we learn today about the structure of DNA and of cells, and 
how these are knit together in a functioning organism, is indispensible 
tomorrow for what is indeed a war against pain, disease, and death. 
There is no fundamental reason why we cannot learn to prevent all of 
the major destroyers of long and happy lives that loom over the world 
today: heart disease, cancer, mental illness, parasitic afflictions, birth 
defects, even untimely aging. These tragic events are not inexorable 
laws of matter and energy-they are side-effects of a natural evolu­
tionary process that is both incomplete in its own script and indifferent 
to the anguish of the human consciousness as we face our own 
mortality. 
Advances against these threats will not come cheaply, and the main 
ones will, as the history of science has shown again and again, come 
from the most unexpected and unprogrammed sources. The careers of 
thousands of investigators are committed to them, and they, in turn, 
require a level of material support that must be justified in competition 
with many short-run social needs. They need moral support as well. 
The ground rules for the ethical involvement of human subjects in 
medical research are under constant scrutiny and revision, and evoke 
an ever more cumbersome bureaucracy of supervision. Above all, the 
lay citizen needs adequate information to be able to confront his own 
soul about the choices ahead-whether to be a passive victim of 
natural disease and disability, or to seize the chance to use new 
knowledge for a rational frame of healthy life. There has been much, 
sometimes hysterical, concern about the risks of medical research and 
the need for public involvement. In my view, the most strident shocks 
to familiar ways will come from the very success of our basic programs 
of health research. No one will cast a vote against "living"; but we 
have certainly not begun to face up to the social problems inherent in 
biological solutions for the prolongation of life, even those that have 
already been achieved in this century. 
The primary responsibility that I avow in my new office is to help 
sustain the traditions of excellence in science for which The Rockefeller 
Institute and University has been justly famous for many decades. 
The creative intellect of its carefully selected and gifted individual 
members is the bedrock of accomplishment of any institution, and 
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they must be furnished an enyironment and resources with which to 
exercise their gifts. The substantial scope, but simple structure and 
coherent goals, of this University offer a unique and attractive chal­
lenge to scientific leadership. Beyond the list of our sixty independent 
laboratories is an overarching opportunity to bring different specialties 
of knowledge and styles of critical thinking together, both to enhance 
scientific excellence and to confront all of these with the practical 
challenges of human disease. The remarkable aspects of The Rocke­
feller University: its appropriate size, traditions, setting, and range of 
studies on one campus-encompassing molecular biology, the behav­
ioral sciences, and the clinic-all offer unparalleled opportunities for 
intellectual adventure and human service. 
This conception of collegial effort is deeply embedded in the moti­
vations both of our original founder and of the many individuals, 
corporations, and foundations that have continued to support the 
programs of The Rockefeller University. At its inception, the federal 
support of biomedical research, mediated primarily through the Na­
tional Institutes of Health, was implemented according to similar 
ideals. Such support is absolutely indispensable and government grants 
now account for half the annual operating budget of this University. 
It is predictable but lamentable that this level of federal involvement 
brings along an egregious degree of centralized management. Most of 
this funding is directed to the "purchase" of specified research results, 
packaged in projects, as if major discovery could be marketed accord­
ing to such specifications. The project grant system, as admirably as 
it has supported major innovations and discoveries in the past, is now 
administered in ways that threaten to disintegrate institutions, to 
discourage the confluence of creative ideas, and to impede opportun­
istic collaborations of basic science and important clinical applications. 
One of the most important functions of a private endowment is a 
countercurrent to the services-rendered concept of the support of 
research. In its place we return to the concept of venture capital 
toward the identification of creative individuals and of collegial 
frameworks better able to achieve the same social ends. 
The need for collegiality and the attenuation of internal obstacles 
to its realization also extend to the relationship between institutions. 
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Happily situated at the center of an extraordinary complex of 
medical institutions-being literally now in the shadow of New York 
and Memorial Hospitals, and immediate neighbors to Cornell Uni­
versity Medical College and the Memorial Sloan-Kettering Cancer 
Center-we have a remarkable opportunity to match our own intel­
lectual style and skills, and dedication to the most basic science, with 
the diverse problems and resources of our neighbors. They are deeply 
preoccupied with medical education and the care of patients on a 
large scale. These are social values of undeniable worth, but distinct 
from what we can off er in tracing the underlying causes of disease. I 
believe we have a particular obligation to focus on preventive health 
applications: but I fear it will be quite a while before the hospitals are 
no longer needed. We must work together to meet our categorical 
social responsibilities, and I am delighted that even in the few weeks 
of my tenure a number of measures for realistic partnership have been 
started with the equally enthusiastic concurrence of our neighbors. 
In closing, may I recall that I was educated in New York, having 
had the privilege of access to Stuyvesant High School and to Columbia 
University and Medical School, to the City's public library system 
and many other institutions that foster intellectual development. 
Having been away for many years and now returned, I feel especially 
keenly how rich are these networks of sources. We are really all non­
matriculated students in a metropolitan super-university. I will cer­
tainly be doing all I can to enjoy this fare for myself and my colleagues, 
and to seek ways in which our own specialized institution can most 
efficiently cooperate with others truly "pro bono humani generis," for the 
benefit of mankind. I am indeed grateful to the Board of Trustees, to 
my colleagues, and to the community of our supporters and well­
wishers for having created such an opportunity. 
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